Press coverage about Female Health Company (The) (NASDAQ:FHCO) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Female Health Company (The) earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.191234375426 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- Edited Transcript of FHCO earnings conference call or presentation 8-Aug-17 12:00pm GMT (finance.yahoo.com)
- Veru Inc. Reports Fiscal Third Quarter Financial Results (finance.yahoo.com)
- Global Contraceptives Market: The Female Health Company, Teva Pharmaceutical, Reckitt Benckiser, Pfizer, Mayer Laboratories (medgadget.com)
- Female Health Company (The) (FHCO) Set to Announce Quarterly Earnings on Tuesday (americanbankingnews.com)
- Following Successful Special Meeting of Stockholders, Veru Healthcare Implements Key Stockholder Proposals (finance.yahoo.com)
Shares of Female Health Company (NASDAQ FHCO) traded down 0.79% during midday trading on Tuesday, hitting $1.26. 53,038 shares of the stock were exchanged. Female Health Company has a 1-year low of $0.72 and a 1-year high of $1.50. The stock’s 50-day moving average price is $1.14 and its 200-day moving average price is $1.07. The firm’s market capitalization is $39.49 million.
Female Health Company (The) (NASDAQ:FHCO) last announced its earnings results on Tuesday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter. Female Health Company (The) had a negative net margin of 29.27% and a negative return on equity of 12.51%. The business had revenue of $2.41 million for the quarter. On average, analysts forecast that Female Health Company will post $0.15 EPS for the current year.
A number of research firms have commented on FHCO. ValuEngine cut shares of Female Health Company (The) from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. HC Wainwright set a $5.00 price objective on shares of Female Health Company (The) and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Finally, Rodman & Renshaw started coverage on shares of Female Health Company (The) in a research report on Wednesday, July 26th. They set a “buy” rating and a $5.00 price objective for the company.
TRADEMARK VIOLATION WARNING: This story was originally posted by BBNS and is the sole property of of BBNS. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://baseballnewssource.com/markets/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-female-health-company-the-nasdaqfhco-stock-price/1410609.html.
In other news, insider Mitchell Shuster Steiner purchased 55,000 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was bought at an average price of $1.27 per share, for a total transaction of $69,850.00. Following the purchase, the insider now owns 645,502 shares of the company’s stock, valued at $819,787.54. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Harry Fisch purchased 24,750 shares of the business’s stock in a transaction dated Monday, May 22nd. The shares were purchased at an average price of $1.02 per share, with a total value of $25,245.00. The disclosure for this purchase can be found here. Insiders have bought a total of 230,569 shares of company stock valued at $266,867 in the last quarter. 10.90% of the stock is owned by corporate insiders.
About Female Health Company (The)
The Female Health Company is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.
Receive News & Ratings for Female Health Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health Company (The) and related companies with our FREE daily email newsletter.